HUTCHMED (China) Ltd (HCM): Revenue
$548.51M
Year ended 2025-12-31
+8.8%
3-year compound annual growth
+19.2%
5-year compound annual growth
+11.9%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $548.51M | -13.0% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $630.20M | -24.8% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $838.00M | +96.5% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $426.41M | +19.7% | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | $356.13M | +56.2% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $227.98M | +11.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $204.89M | -4.3% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $214.11M | -11.2% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $241.20M | +11.6% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $216.08M | +21.3% | 2019-03-11, From 2016-01-01 |
| 2015-12-31 | $178.20M | +104.1% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $87.33M | n/a | 2017-03-13, From 2014-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $548.51M | -13.0% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $564.17M | +17.0% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $521.31M | +54.7% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $502.08M | +126.3% |
| Insmed Inc (INSM) | 2025-12-31 | $606.42M | +66.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $606.88M | -14.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.73M | +110.5% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $616.29M | +87.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗